PT1198585E - Processo para caracterizar uma condição biológica usando perfis calibrados da expressão de genes - Google Patents

Processo para caracterizar uma condição biológica usando perfis calibrados da expressão de genes Download PDF

Info

Publication number
PT1198585E
PT1198585E PT00944977T PT00944977T PT1198585E PT 1198585 E PT1198585 E PT 1198585E PT 00944977 T PT00944977 T PT 00944977T PT 00944977 T PT00944977 T PT 00944977T PT 1198585 E PT1198585 E PT 1198585E
Authority
PT
Portugal
Prior art keywords
data
profile
panel
profile data
sample
Prior art date
Application number
PT00944977T
Other languages
English (en)
Portuguese (pt)
Inventor
Victor Tryon
Michael P Bevilacqua
Danute M Bankaitis-Davis
John Cheronis
Original Assignee
Source Precision Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26839213&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1198585(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Source Precision Medicine Inc filed Critical Source Precision Medicine Inc
Publication of PT1198585E publication Critical patent/PT1198585E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT00944977T 1999-06-28 2000-06-28 Processo para caracterizar uma condição biológica usando perfis calibrados da expressão de genes PT1198585E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14154299P 1999-06-28 1999-06-28
US19552200P 2000-04-07 2000-04-07

Publications (1)

Publication Number Publication Date
PT1198585E true PT1198585E (pt) 2007-09-20

Family

ID=26839213

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00944977T PT1198585E (pt) 1999-06-28 2000-06-28 Processo para caracterizar uma condição biológica usando perfis calibrados da expressão de genes

Country Status (13)

Country Link
EP (1) EP1198585B1 (enExample)
JP (1) JP2004528526A (enExample)
KR (1) KR20020079364A (enExample)
AT (1) ATE364721T1 (enExample)
AU (1) AU784233B2 (enExample)
CA (1) CA2378008A1 (enExample)
CY (1) CY1107733T1 (enExample)
DE (1) DE60035196T2 (enExample)
DK (1) DK1198585T3 (enExample)
ES (1) ES2290046T3 (enExample)
IL (2) IL147349A0 (enExample)
PT (1) PT1198585E (enExample)
WO (1) WO2001025473A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473528B2 (en) 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US7590493B2 (en) 2000-07-31 2009-09-15 Ocimum Biosolutions, Inc. Methods for determining hepatotoxins
AUPR480901A0 (en) * 2001-05-04 2001-05-31 Genomics Research Partners Pty Ltd Diagnostic method for assessing a condition of a performance animal
EP1392871A4 (en) 2001-05-22 2006-04-19 Gene Logic Inc MODELING MOLECULAR TOXICITY
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
CA2452897A1 (en) * 2001-07-10 2003-08-21 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
US7447594B2 (en) 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
ES2376422T3 (es) 2001-08-21 2012-03-13 Ventana Medical Systems, Inc. Método y ensayo de cuantificación para determinar el estado c-kit/scf/pakt.
CA2466502A1 (en) 2001-11-09 2003-05-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US7469185B2 (en) 2002-02-04 2008-12-23 Ocimum Biosolutions, Inc. Primary rat hepatocyte toxicity modeling
DE60324810D1 (de) 2002-09-20 2009-01-02 New England Biolabs Inc HELICASE-ABHuNGIGE AMPLIFIKATION VON NUKLEINSUREN
US7662594B2 (en) 2002-09-20 2010-02-16 New England Biolabs, Inc. Helicase-dependent amplification of RNA
AU2002952696A0 (en) * 2002-11-14 2002-11-28 Genomics Research Partners Pty Ltd Status determination
US7778782B1 (en) 2002-12-17 2010-08-17 Entelos, Inc. Peroxisome proliferation activated receptor alpha (PPARα) signatures
US7396645B1 (en) 2002-12-17 2008-07-08 Entelos, Inc. Cholestasis signature
BR0317612A (pt) * 2002-12-19 2005-12-06 Source Precision Medicine Inc Identificação, monitoração e tratamento de doença infecciosa e caracterização de condições inflamatórias relacionadas com doença infecciosa empregando perfis de expressão de gene
US7422854B1 (en) 2002-12-20 2008-09-09 Entelos, Inc. Cholesterol reduction signature
US7519519B1 (en) 2002-12-20 2009-04-14 Entelos, Inc. Signature projection score
AU2003901196A0 (en) * 2003-03-17 2003-04-03 Commonwealth Scientific And Industrial Research Organisation Analysis method
CA2534661A1 (en) 2003-08-08 2005-02-17 Genenews Inc. Osteoarthritis biomarkers and uses thereof
JPWO2005087924A1 (ja) * 2004-02-18 2008-01-31 株式会社三重ティーエルオー Ｄｎａチップ並びに疾患関連遺伝子の抽出方法
WO2006138561A2 (en) 2005-06-16 2006-12-28 Source Mdx Gene expression profiling for identification and monitoring of multiple sclerosis
AU2006294477A1 (en) 2005-09-27 2007-04-05 Source Mdx Gene expression profiling for identification monitoring and treatment of rheumatoid arthritis
US20080227655A1 (en) * 2006-05-16 2008-09-18 Michael Bevilacqua Assessment of effect of an agent on a human biological condition using rodent gene expression panels
US20100196889A1 (en) 2006-11-13 2010-08-05 Bankaitis-Davis Danute M Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer
CA2730277A1 (en) 2008-07-08 2010-01-14 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for predicting the survivability of prostate cancer subjects
CA2748823A1 (en) 2009-01-06 2010-07-15 Source Precision Medicine, Inc. D/B/A Source Mdx Gene expression profiling for the identification, monitoring, and treatment of prostate cancer
US9074248B1 (en) 2012-12-18 2015-07-07 Qiagen Gmbh Primers for helicase dependent amplification and their methods of use
CN103525926B (zh) * 2013-10-08 2016-03-23 浙江大学 一种基于基因表达谱的药物毒性个体易感性基因标志物的筛选方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643765A (en) * 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5922184A (en) * 1997-07-21 1999-07-13 Bio-Rad Laboratories, Inc. Computer-directed detection of paraproteins
AU722819B2 (en) * 1996-12-06 2000-08-10 Urocor, Inc. Diagnosis of disease state using mRNA profiles
US5968784A (en) * 1997-01-15 1999-10-19 Chugai Pharmaceutical Co., Ltd. Method for analyzing quantitative expression of genes
GB9704444D0 (en) * 1997-03-04 1997-04-23 Isis Innovation Non-invasive prenatal diagnosis
AU9217198A (en) * 1997-09-03 1999-03-22 Oncormed Method for predicting prognosis and treatment response for genetically based abnormalities
WO1999013113A1 (en) * 1997-09-12 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. Non-competitive co-amplification methods
ATE291097T1 (de) * 1997-10-31 2005-04-15 Affymetrix Inc A Delaware Corp Expressionsprofile in adulten und fötalen organen

Also Published As

Publication number Publication date
KR20020079364A (ko) 2002-10-19
WO2001025473A1 (en) 2001-04-12
ES2290046T3 (es) 2008-02-16
ATE364721T1 (de) 2007-07-15
CA2378008A1 (en) 2001-04-12
AU5898500A (en) 2001-05-10
WO2001025473A9 (en) 2002-08-08
EP1198585B1 (en) 2007-06-13
IL147349A (en) 2011-12-29
DK1198585T3 (da) 2007-10-15
AU784233B2 (en) 2006-02-23
IL147349A0 (en) 2002-08-14
JP2004528526A (ja) 2004-09-16
EP1198585A1 (en) 2002-04-24
DE60035196T2 (de) 2008-02-21
CY1107733T1 (el) 2013-04-18
DE60035196D1 (de) 2007-07-26

Similar Documents

Publication Publication Date Title
PT1198585E (pt) Processo para caracterizar uma condição biológica usando perfis calibrados da expressão de genes
Voisin et al. An epigenetic clock for human skeletal muscle
Shahrajabian et al. Survey on multi-omics, and multi-omics data analysis, integration and application
Hoang et al. Epigenome-wide DNA methylation and pesticide use in the agricultural lung health study
Harrison et al. Fungal microbiomes are determined by host phylogeny and exhibit widespread associations with the bacterial microbiome
Matheson et al. Culture as an ingredient of personalized medicine
CN102289606A (zh) 药物的筛选方法以及药物组合设计方法
Pollard Jr et al. A computational model to define the molecular causes of type 2 diabetes mellitus
Shamloo et al. Integrative CRISPR activation and small molecule inhibitor screening for lncRNA mediating BRAF inhibitor resistance in melanoma
Wang et al. Integrative decomposition procedure and Kappa statistics for the distinguished single molecular network construction and analysis
Origgi et al. Francisella tularensis infection in a stone marten (Martes foina) without classic pathological lesions consistent with tularemia
Colvin et al. Lung and heart biology of the Dp16 mouse model of Down syndrome: implications for studying cardiopulmonary disease
Demirci et al. Investigating vitreous cytokines in choroidal melanoma
EP4204591B1 (en) Method of assessing the circadian rhythm of a subject having cancer and/or assessing a timing of administration of a medicament to said subject having cancer
JP2009509545A5 (enExample)
Zou et al. Decreased tertiary lymphoid structures in lung adenocarcinomas with ALK rearrangements
Wang et al. Noncoding RNAs serve as the deadliest regulators for cancer
Liu et al. 78 Wildfire smoke-driven PM2. 5 and its association with persistent respiratory symptoms and repeated asthma exacerbations among adults with asthma
Sharma et al. Metabolomics: Recent Advances and Future Prospects Unveiled
Adila PP455 Cancer incidence and mortality in Southeast Asia and their relationship with human development index levels
Wang et al. A seed-based approach to identify risk disease sub-networks in human lung cancer
Frahm Metabolomics using dissolution DNP-NMR
Qiu Understanding Aging at Multi-Scale Using Explainable AI
Clark et al. Characterization of Phenotypes Generated by Expression of the Bwa enzyme in Drosophila melanogaster to Develop a Colorectal Cancer Treatment Screen
Auerbach et al. Epigenome-Wide DNA Methylation and Pesticide Use in the Agricultural Lung Health Study